| Reference |
|---|
Costa S, Soares M, Poleto Bragato J, Dos Santos M, Rebech G, de Freitas J, et al. MicroRNA-194 regulates parasitic load and IL-1β-dependent nitric oxide production in the peripheral blood mononuclear cells of dogs with leishmaniasis. PLoS Negl Trop Dis. 2024;18:e0011789 pubmed publisher |
Baxarias M, Donato G, Mateu C, Salichs M, Homedes J, Mir xf3 G, et al. A blinded, randomized and controlled multicenter clinical trial to assess the efficacy and safety of Leisguard® as an immunotherapeutic treatment for healthy Leishmania infantum-seropositive dogs. Parasit Vectors. 2023;16:344 pubmed publisher |
Pelst M, H xf6 bart C, de Rooster H, Devriendt B, Cox E. Immortalised canine buccal epithelial cells' CXCL8 secretion is affected by allergen extracts, Toll-like receptor ligands, IL-17A and calcitriol. Vet Res. 2022;53:72 pubmed publisher |
Maekawa N, Konnai S, Asano Y, Sajiki Y, Deguchi T, Okagawa T, et al. Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy. Sci Rep. 2022;12:9265 pubmed publisher |
Bragato J, Rebech G, Freitas J, Santos M, Costa S, Eug xea nio F, et al. miRNA-21 regulates CD69 and IL-10 expression in canine leishmaniasis. PLoS ONE. 2022;17:e0265192 pubmed publisher |
Mart xed nez Orellana P, Gonz xe1 lez N, Baldassarre A, xc1 lvarez Fern xe1 ndez A, Ordeix L, Paradies P, et al. Humoral Responses and Ex Vivo IFN-γ Production after Canine Whole Blood Stimulation with Leishmania infantum Antigen or KMP11 Recombinant Protein. Vet Sci. 2022;9: pubmed publisher |
Abbott J, Chan S, MacBeth M, Crooks J, Hancock C, Knight V, et al. Fluctuations in quality of life and immune responses during intravenous immunoglobulin infusion cycles. PLoS ONE. 2022;17:e0265852 pubmed publisher |
Verde M, Villanueva Saz S, Loste A, Marteles D, Pereboom D, Conde T, et al. Comparison of circulating CD4+, CD8+ lymphocytes and cytokine profiles between dogs with atopic dermatitis and healthy dogs. Res Vet Sci. 2022;145:13-20 pubmed publisher |
Igase M, Nemoto Y, Itamoto K, Tani K, Nakaichi M, Sakurai M, et al. A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs. Sci Rep. 2020;10:18311 pubmed publisher |
Velez R, Domenech E, Rodriguez Cortes A, Barrios D, Tebar S, Fernández Arévalo A, et al. Evaluation of canine leishmaniosis vaccine CaniLeish® under field conditions in native dog populations from an endemic Mediterranean area-A randomized controlled trial. Acta Trop. 2020;205:105387 pubmed publisher |
Kim Y, Lee S, Kim C, Lee J, Yu D, Ahn S, et al. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells. BMC Vet Res. 2019;15:339 pubmed publisher |
Wheat W, Chow L, Kuzmik A, Soontararak S, Kurihara J, Lappin M, et al. Local immune and microbiological responses to mucosal administration of a Liposome-TLR agonist immunotherapeutic in dogs. BMC Vet Res. 2019;15:330 pubmed publisher |
Alcolea P, Alonso A, Esteban A, Peris P, Cortés A, Castillo J, et al. IL12 p35 and p40 subunit genes administered as pPAL plasmid constructs do not improve protection of pPAL-LACK vaccine against canine leishmaniasis. PLoS ONE. 2019;14:e0212136 pubmed publisher |
Oliveira Silva K, Marin Chiku V, Luvizotto Venturin G, Correa Leal A, de Almeida B, de Rezende Eugênio F, et al. PD-1 and PD-L1 regulate cellular immunity in canine visceral leishmaniasis. Comp Immunol Microbiol Infect Dis. 2019;62:76-87 pubmed publisher |
Chow L, Johnson V, Coy J, Regan D, Dow S. Mechanisms of Immune Suppression Utilized by Canine Adipose and Bone Marrow-Derived Mesenchymal Stem Cells. Stem Cells Dev. 2017;26:374-389 pubmed publisher |
Resende L, Aguiar Soares R, Gama Ker H, Roatt B, Mendonça L, Alves M, et al. Impact of LbSapSal Vaccine in Canine Immunological and Parasitological Features before and after Leishmania chagasi-Challenge. PLoS ONE. 2016;11:e0161169 pubmed publisher |
Shahbazi M, Zahedifard F, Taheri T, Taslimi Y, Jamshidi S, Shirian S, et al. Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis. PLoS ONE. 2015;10:e0132794 pubmed publisher |
Costa Pereira C, Moreira M, Soares R, Marteleto B, Ribeiro V, França Dias M, et al. One-year timeline kinetics of cytokine-mediated cellular immunity in dogs vaccinated against visceral leishmaniasis. BMC Vet Res. 2015;11:92 pubmed publisher |
Figueiredo M, Deoti B, Amorim I, Pinto A, Moraes A, Carvalho C, et al. Expression of regulatory T cells in jejunum, colon, and cervical and mesenteric lymph nodes of dogs naturally infected with Leishmania infantum. Infect Immun. 2014;82:3704-12 pubmed publisher |
Maekawa N, Konnai S, Ikebuchi R, Okagawa T, Adachi M, Takagi S, et al. Expression of PD-L1 on canine tumor cells and enhancement of IFN-? production from tumor-infiltrating cells by PD-L1 blockade. PLoS ONE. 2014;9:e98415 pubmed publisher |
Aparicio Burgos J, Ochoa García L, Zepeda Escobar J, Gupta S, Dhiman M, Martínez J, et al. Testing the efficacy of a multi-component DNA-prime/DNA-boost vaccine against Trypanosoma cruzi infection in dogs. PLoS Negl Trop Dis. 2011;5:e1050 pubmed publisher |
Travi B, Osorio E, Saldarriaga O, Cadena H, Tabares C, Peniche A, et al. Clinical, parasitologic, and immunologic evolution in dogs experimentally infected with sand fly-derived Leishmania chagasi promastigotes. Am J Trop Med Hyg. 2009;81:994-1003 pubmed publisher |
Fernandes A, Costa M, Coelho E, Michalick M, de Freitas E, Melo M, et al. Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. Vaccine. 2008;26:5888-95 pubmed publisher |
